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ABSTRACT
Background: Anaemia is common in patients who survive critical illness and is associated with high 
levels of fatigue and poor quality of life. In non-critically ill patients, treating anaemia with 
intravenous iron has resulted in meaningful improvements in quality of life, but uncertainties 
regarding the benefits, risks, timing and optimal route of iron therapy in survivors of critical illness 
remain. 
Methods / Design: INtravenous Iron to Treat Anaemia following CriTical care (INTACT) is an open-
label, feasibility, parallel group, randomised controlled trial (RCT) with 1:1 randomisation to either 
intravenous iron (1000mg ferric carboxymaltose) or usual medical care. The primary objective is to 
assess the feasibility of a future, multicentre RCT. Participants will be followed up for up to 90 days 
post-randomisation. The primary outcome measures, which will be used to determine feasibility, are 
recruitment and randomisation rates, protocol adherence and completeness of follow-up. Secondary 
outcome measures include collecting clinical, laboratory, health-related quality of life and safety 
data to inform the power calculations of a future definitive trial. 
Conclusion: Improving recovery from critical illness is a recognised research priority. Whether or not 
correcting anaemia, with intravenous iron, improves health-related quality of life and recovery 
requires further investigation. If so, it has the potential to become a rapidly translatable 
intervention. Prior to embarking on a phase III multicentre trial, a carefully designed and 
implemented feasibility trial is essential. 
Key words: Anaemia; Intravenous Iron; Intensive Care; Clinical Trial; Quality of life
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INTRODUCTION
Background 
Anaemia is a very common problem in intensive care units (ICUs) affecting 60-80% of patients and is 
associated with adverse outcomes.1, 2  Anaemia persists until hospital discharge and in some studies 
up to 6 months following ICU discharge, and is associated with fatigue and poor health-related 
quality of life (HRQoL).3-5 
Iron-restricted erythropoiesis resulting from anaemia of inflammation is extremely common 
in ICU patients and may occur through absolute iron deficiency, functional iron deficiency or iron 
sequestration. Dysregulated iron homeostasis is associated with adverse outcomes in ICU patients.6 
Our understanding of iron homeostasis has been improved by the discovery of hepcidin – the master 
regulator of body iron status. Hepcidin is a small peptide produced by the liver and acts by inhibiting 
the function of ferroportin, the sole cellular exporter of iron. Hepcidin blocks duodenal iron 
absorption and results in iron trapping within macrophages and hepatocytes subsequently 
decreasing the availability of iron for erythropoiesis.7 Current markers of iron status (e.g. ferritin, 
transferrin saturation) have limited utility in critically ill patients as the relationship between these 
markers and iron status is heavily confounded by inflammation. Hepcidin may be a better marker of 
iron status in critically ill patients, even in the presence of inflammation,8, 9 and recent work supports 
the hypothesis that critically ill patients have potentially iron-responsive anaemia which may not be 
detectable with currently available tests. One study suggested that 35% of ICU survivors developed 
evidence of iron deficiency six months after ICU stay.4 
In other contexts, intravenous (IV) iron therapy has been shown to be effective in treating 
anaemia with subsequent improvements in quality of life.10-13 IV iron is able to bypass hepcidin-
induced restriction of iron.14 Despite this, safety concerns regarding the risk of infection caused 
intravenous iron infusion remain. Iron is essential for bacterial growth and exogenous iron 
administration has been shown to worsen shock and lung injury in canine experimental models of 
pneumonia.15 RCTs have not always included infection as a pre-defined end point and therefore the 
risk in critically ill patients remains uncertain.12, 16, 17 
Rationale for a trial
ICU survivors experience poor HRQoL, reduced physical function and fatigue.18-20 Improving recovery 
from critical illness has been identified as a key research priority by the NIHR critical care portfolio 
and the James Lind Alliance. Evidence from observational studies suggests that untreated anaemia 
may, in part, be contributing to these symptoms. 
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Attempts to treat anaemia during acute critical illness have so far been unsuccessful. RCTs of 
iron supplementation in ICU patients have failed to demonstrate any evidence of benefit.17, 21 This 
could partly be explained by limitations in trial design as studies were underpowered and there was 
wide variation in patient populations and iron administration regimes.17 Biological reasons to explain 
this lack of benefit could be due a hyporeactive bone marrow, secondary to the acute inflammatory 
response, that may not respond to exogenous iron administration. The peak effect of iron may also 
not be observed until 2-3 weeks after administration.14, 17 22, 23 This suggests that any relative risks 
and benefits of iron probably depend on the timing of administration. 
We hypothesise that treating anaemia when patients are recovering from critical illness, 
when the iron and erythropoietic profiles are more favourable, may be a more suitable time point 
for intervention, than during the acute phase of critical illness. A large, multicentre RCT is needed to 
answer this question but there are uncertainties regarding recruitment and follow-up rates, 
variability in haemoglobin concentrations in the post-ICU period and choice of optimal outcome 
measures.18 We have therefore designed the INTACT feasibility RCT, with the primary aim of 
assessing recruitment, randomisation and follow-up rates to inform the design of a future 
adequately powered multicentre trial.
Objectives
Primary objective
To assess the feasibility of a future large multicentre RCT of intravenous iron to treat anaemia in 
patients recovering from critical illness in intensive care.
Secondary objective
To collect clinical, laboratory and health-related quality of life data to inform the power calculations 
and health economic evaluations of any future definitive trial. 
Trial design
INTACT is an open-label, feasibility, parallel group, randomised controlled trial with 1:1 
randomisation to either intervention or usual medical care. The trial is being co-ordinated by the 
Oxford Clinical Trials Research Unit (OCTRU) and sponsored by the University of Oxford. The funding 
is provided by the National Institute for Health Research (NIHR) as part of a Doctoral Research 
Fellowship (DRF-2017-10-094). The trial is being conducted in accordance with the principles of the 
Declaration of Helsinki and Good Clinical Practice. 
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METHODS
Participants, interventions and outcomes
Study setting
This feasibility RCT is being undertaken in three general adult UK ICUs (John Radcliffe Hospital, 
Oxford; Edinburgh Royal Infirmary, Edinburgh; Royal Berkshire Hospital, Reading) which have a 
proven track record in ICU research.
Eligibility criteria
Written, informed consent is obtained from participants prior to any study procedures taking place. 
Patients eligible for the study must comply with all of the following before randomisation:
 Requirement for ICU (Level 2 or 3 support) for 24 hours and now deemed medically stable 
for discharge from ICU by the attending physician
 Last measured laboratory Hb 100 g.l-1
Patients are excluded if they meet any of the following criteria:
 Planned palliative care
 Planned home ventilation
 Primary neurological diagnosis with little/no rehabilitation potential
 Known hypersensitivity to iron
 Immunosuppressive therapy for organ transplant
 IV iron or erythropoietin treatment in the previous 4 weeks
 Pregnancy (breastfeeding is not an exclusion criterion)
 Personal or family history of iron overload disorders such as haemachromatosis or 
previously documented ferritin >1200 ng.ml-1 and/or transferrin saturation >50%
 History of severe asthma, eczema or atopic allergy
 Known severe chronic liver disease (e.g. Child-Pugh C or above)
 Haemodialysis dependent chronic kidney disease
 Acute uncontrolled infection – as judged by the treating clinician (e.g. ongoing bacteraemia or 
non-resolving sepsis) or patient expected to be on non-prophylactic antibiotics for greater 
than 14 days.
The inclusion and exclusion criteria are designed to include participants who reflect a general 
population of survivors of critical illness with moderate to severe anaemia, who may benefit from 
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the intervention, and exclude patients who are unlikely to benefit or at increased risk of adverse 
events from IV iron.
Intervention 
In the intervention arm, 1000mg of ferric carboxymaltose is diluted in 100 ml of 0.9% saline and 
administered as an IV infusion over a minimum of 15 minutes. The dosing of ferric carboxymaltose is 
based on the maximum dose that can safely be given according the Summary of Product 
Characteristics (SmPC) within a reasonable time period. Participants are closely monitored for signs 
of hypersensitivity during the infusion and for at least 30 minutes after the treatment. The 
intervention can be administered at any time between ICU and hospital discharge. For participants 
who weigh less than 50 kg, the dose would be adjusted to 20 mg.kg-1.
Usual medical care
Usual medical care consists of routine ward based care including observation with monitoring and 
transfusion when required. Current guidelines advocate adopting a restrictive transfusion policy, 
with the exception of certain groups of patients such as those with ischaemic heart disease.24 It is 
not routine practice to administer IV iron in patients recovering from critical illness at present. Any 
decision to commence iron therapy in this group would be at the discretion of the treating physician 
and independent of the study and would be recorded in the Case Report Forms (CRFs). 
Participant timeline
This is highlighted in Figure 1. 
Outcome measures
Primary outcome measures:
 Recruitment and randomisation rates overall and by centre
 Protocol adherence, defined as ‘number of participants allocated to the intervention who go 
on to the receive the study drug’
 Completion rates of HRQoL questionnaires
Secondary outcome measures:
 Nosocomial infection
 Mortality 
 Hospital length of stay
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 Changes in laboratory haematological (e.g. Hb) and iron profiles (e.g. ferritin) from baseline 
to 28 and 90 days post-randomisation
 Changes in Multidimensional Fatigue Inventory-20 (MFI-20), Functional Assessment of 
Chronic Illness Therapy-Fatigue (FACIT-F) and EuroQol-5D-5L (EQ-5D-5L) questionnaire 
scores from baseline to 28 and 90 days post-randomisation
 Healthcare resource use.
Sample size
As this is a feasibility study not aiming to assess treatment effects, we have not undertaken a formal 
power calculation. At the John Radcliffe Hospital (which will be the main recruitment centre for this 
trial) approximately 800 patients are admitted to the ICU each year. Of these 120 patients are 
elective post-operative admissions who would be expected to stay less than 48 hours and of the 
remaining 680 patients, assuming unit mortality of 14%, 584 would be expected to survive ICU. 
Based on pre-trial work and previous studies, 50% (292 patients) would leave ICU with a Hb of ≤100 
g.l-1 .25 Assuming 30-40% enrolment, we expect to enrol on average 100 participants per year 
(approximately 2 participants per week) at this site. From the three sites it is anticipated that 130 
patients will be recruited over a 12month recruitment period.
Assignment of interventions
Randomisation
Eligible participants are randomised on a 1:1 ratio to receive either the intervention or usual medical 
care using minimisation on a secure web-based system controlled and managed by the Oxford 
Clinical Trials Research Unit (OCTRU), stratified on anaemia severity (Hb <80 g.l-1 versus 80-100 g.l-1) 
and participant ICU length of stay (<7 days versus 7 days). 
Blinding 
We have opted not to use a placebo study drug. This is because ferric carboxymaltose is a 
challenging substance to blind due to its rusty brown colour. 
Data collection, management and analysis
Data collection
Data are collected using paper CRFs and then transferred to a validated electronic data entry system. 
Clinical data is collected at baseline (pre-randomisation) and hospital discharge. Laboratory and 
HRQoL data is collected at baseline, and 28 and 90-days post-randomisation. This is outlined in the 
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study schematic in Figure 2 and detailed in Table 1. Laboratory data will include serial measurements 
of hepcidin throughout the study period. 
The EQ-5D-5L is a generic preference-based measure of health that is recommended by NICE 
for economic valuations. The MFI-20 is a 20-item self-reporting score designed and validated to 
measure fatigue across 5 domains – general fatigue, physical fatigue, mental fatigue, reduced 
motivation and reduced activity.26 Scores can range from 4 to 20, with higher values indicative of 
increased fatigue levels. Its use in ICU survivors has been described previously.4 The FACIT-F is a 
subscale of a questionnaire developed to assess anaemia-related symptoms in patients with 
cancer.27It consists of 13 items referring to the previous seven days. The final scores range from 0-52 
with higher scores representing less fatigue. It has been validated to assess fatigue in ICU survivors.28 
Approximately 15-20 minutes will be required to complete all three questionnaires. Participants may 
ask for help completing the questionnaires from relatives, bedside nurses or a member of the 
research team. This is felt to be reasonable as problems with concentration and attention are not 
uncommon in critically ill patients.
Retention
Participation retention in ICU trials is challenging.28, 29, 30 To minimise loss to follow-up we will invite 
participants to our weekly ICU follow-up clinic with full reimbursement of travel costs. If participants 
are unable to attend, a member of the research team will undertake a home visit with appropriate 
safe guards in place. Telephone follow-up is offered for participants who live outside a reasonable 
geographic follow-up area to collect HRQoL data.
Data management
A Data Management Plan has been produced for the study which includes references to 
confidentiality, access and security arrangements and is available on request from the INTACT study 
office. In brief, staff at participating centres collect data on paper CRFs, which is then be entered into 
a password-protected online database (OpenClinica®), located on a secure University server. The 
database has validation on data fields. Paper CRFs are stored in the Investigator Site File under 
secure conditions. Paper copies of the consent forms will also be logged into the trial database and 
then scanned and stored electronically in the e-Trial Master File.
Statistical analysis
Results will be reported in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) extension to randomised pilot and feasibility trials.31 Recruitment and follow-up rates 
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are the main drivers for the feasibility design on the basis that unless reasonable rates can be 
achieved no formal trial will be possible. Recruitment rate will be calculated by the number of 
participants randomised as a proportion of total number of eligible participants. Rates will be 
estimated based on data collected and a 95% confidence interval determined for these measures. 
If the estimated recruitment and follow-up rates are such that a multicentre definitive trial is 
possible, then no formal analysis will be undertaken and data from the feasibility study will be 
locked and carried over into the definitive trial. No formal analysis of treatment efficacy will be 
undertaken in this case. 
Statistical power calculations for the definitive trial will be reviewed based on blinded data 
collected in this feasibility trial. A ‘traffic light’ system shown in Table 2 will be used as a guide for 
progression to a definitive trial.31 If the definitive trial is not feasible, or funding for the definitive 
trial cannot be obtained, data analysis will be undertaken and reported in the conventional manner. 
Descriptive statistics will be used to describe the demographic and clinical characteristics 
between the two groups at baseline. Clinical outcome data will be analysed depending on the type 
of variables: for continuous variables, the difference in the means and corresponding 95% 
confidence intervals and Analysis of Covariance, adjusting for baseline values will be used for 
comparing the two groups. For categorical variables, the number and percentage of participants in 
each category will be reported and Chi-squared tests will be used for comparing the two treatment 
groups. If the variables are not normally distributed, alternative non-parametric tests will be used for 
analysis. Analyses will be conducted on the intention-to-treat (ITT) (analysed as randomised) and 
per-protocol (as ITT but with protocol violators excluded) populations. As this is a small study, 
treatment effects are likely to have wide confidence intervals and consequently inferences will be 
tentative and reported as such. Tests will be two-sided and considered to provide evidence for a 
significant difference if p-values are less than 0.05. 
Missing data
Reasons for missing data, loss to follow-up and participant withdrawals will be carefully considered, 
reported and patterns of ‘missingness’ will be explored. Missing data will be minimised by collecting 
the minimum amount of data required and data queries will be resolved prior to analysis. We have 
stated that the analysis will be on ITT basis and a per-protocol basis if the study is not considered 
feasible. There will not be a formal statistical analysis plan and therefore deviations from it are not 
anticipated. Any deviations from the analysis presented will be reported in the final study report. 
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Monitoring and safety
Data monitoring
A trial monitoring plan has been developed and will comply with the principles of Good Clinical 
Practice (GCP). As this is a small study with a short duration, there is no formal Data Monitoring 
Committee. Instead, there is a Trial Oversight Group (TOG), which includes independent clinicians 
experienced in the fields of clinical trials, intensive care and haematology along with an independent 
statistician. The TOG will work closely with the Trial Management Group (TMG) and provide overall 
supervision of the study to ensure it is being conducted in accordance with GCP. A charter containing 
the details of the members, roles and responsibilities and planned method of functioning has been 
created and is available on request from the INTACT study office.
Safety
Participants surviving ICU are at a high-risk of adverse events (AEs) and serious adverse events (SAEs) 
secondary to their underlying disease process and/or expected complications of their critical illness. 
Therefore, only SAEs that might reasonably be a consequence of participation in the trial and are 
judged by the investigator to not be due to the underlying disease or expected complications of their 
critical illness will be reported. Ferric carboxymaltose is a drug with a well-known safety profile. The 
following rare events, if serious, must be reported on the trial specific SAE form:
 Anaphylactic / anaphylactoid reactions
 Loss of consciousness / syncope
 Bronchospasm
 Angioedema and facial oedema
 Severe anaemia (Hb <80 g.l1) at 28 and/or 90 day follow-up
All SAEs will be submitted to the INTACT trial office within 24 hours of the investigator becoming 
aware. 
Auditing
OCTRU will conduct a one-off audit of the study in accordance with the trial monitoring plan. Access 
to data will also be granted to authorised representatives from the Sponsor, host institution and the 
regulatory bodies to permit trial-related monitoring, audits and inspections. A trial monitoring plan is 
available on request from the INTACT study office. 
Ethics and dissemination 
Page 11 of 30
https://mc.manuscriptcentral.com/inc
Journal of the Intensive Care Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
11
Regulatory and ethics approval
This is a feasibility study of an investigational medicinal product which is broadly being used within 
its licensing indication. According to the Medicines and Healthcare products Regulatory Agency 
(MHRA), this trial has been categorised as Type A (no higher than the risk of standard care) as ferric 
carboxymaltose is indicated for the treatment of iron deficiency when oral preparations are likely to 
be ineffective or cannot be used. Clinical Trial Authorisation from the MHRA was received on 17th 
July 2018.
A favourable ethical opinion was obtained from South Central – Berkshire B Research Ethics 
Committee on 7th July 2018 (18/SC/0308). Health Research Authority approval was obtained on 20th 
July 2018. A favourable opinion for a substantial amendment was obtained on 18th April 2019 (see 
Appendix 1).
Consent
Any participants that are deemed potentially suitable will be asked by a member of the clinical team 
if a member of research team could come along and discuss a research study that they may be 
eligible for. The clinical team will also provide the participant with a Participant Information Leaflet. 
All eligible participants who agree verbally to be approached by the research team will be allocated a 
screening number and entered into the screening log, which will be kept in the Investigator Site File 
(ISF). The screening log will be completed and maintained by an appropriately trained member of 
the research team. Where a participant agrees to take part in the study, a copy of the consent form 
will also be filed in the medical notes. The participant must personally sign and date the latest 
approved version of the Informed Consent Form (ICF) before any study specific procedures are 
performed.
Confidentiality 
The research team will ensure that the participants’ anonymity is maintained. The participants will 
be identified only by a participant code on all study documents and the study CRF database, with the 
exception of the personal identifiers database, which will be held separately to the CRF database. 
The personal identifiers database will be used for the sole purpose of arranging study follow-up 
visits. All documents will be stored securely and only accessible by study staff and authorised 
personnel. 
Dissemination policy
The TMG will form the basis of the writing committee and advise on the nature of the publications. 
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The study will be reported in accordance with the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines and the pilot and feasibility extension.31 The study findings will be presented 
at national and international meetings and the results will be published in a high quality, peer 
reviewed, open-access (via Pubmed) journal. Ongoing study updates will also be provided on the 
OCTRU website (intact.octru.ox.ac.uk). 
DISCUSSION
The problem of anaemia after critical illness is increasingly being recognised. With guidelines 
advocating restrictive transfusion practices, it is likely that even more ICU survivors will be 
discharged from hospital with anaemia. No large clinical trial has been undertaken to address the 
correction of anaemia by the use of IV iron in ICU survivors. INTACT is an open-label, feasibility, 
randomised controlled trial designed to answer whether a future large RCT can be undertaken. 
The trial design is pragmatic and aims to deliver the intervention at any point between ICU 
and hospital discharge. The current post-ICU median (IQR) length of stay in our institution is 10 (6-
23) days. In order to maximise retention and minimise participant burden, we will offer 
reimbursement of any travel expenses incurred, and conduct home visits as necessary. This 
approach was successfully used in a recent RCT evaluating the effect of a physical rehabilitation 
package in patients recovering from critical care where there was only a 10% loss to follow-up at 3 
months.33
A limitation of our study is the lack of a placebo infusion. The rusty brown colour of ferric 
carboxymaltose makes it a challenging substance to blind. This could potentially result in bias, 
particularly for HRQoL measures. However, a recent large RCT of post-operative intravenous iron in 
patients undergoing major elective surgery also used a usual care control group and observed no 
differences in Short Form-36 (SF-36) scores at 12 weeks post-treatment.34 As part of our study we 
will be asking participants at the 90-day follow-up whether or not they remember which group they 
were randomised to. We will review the decision regarding a placebo infusion for any future RCT.
In conclusion, INTACT is designed to determine whether or not a large RCT of treating 
anaemia with IV iron in patients recovering from intensive care is feasible. If so, it has the potential 
to rapidly become a translatable intervention. The trial opened to recruitment in September 2018 
and is anticipated to close in December 2019. 
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Appendix 1: History of protocol amendments
Amendment No. Protocol 
Version No.
Date issued Details of Changes made
1 2.0 13Jul2018 Addition of pregnancy testing, specification 
of timeframe (24 hours) for notification of 
SAE to CI, and mention of heart rate and 
blood pressure monitoring before, during 
and after drug administration
2 3.0 06Mar2019 Revision of inclusion and exclusion criteria, 
including definition of active infection. 
Greater clarity on recruitment process. 
Dose adjustment for participants weighing 
less than 50 kg. Addition of telephone 
follow-up. Addition of Royal Berkshire 
Hospital as a recruitment site. 
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Figure 1. Study flow chart
Patient deemed fit for ICU discharge and screened for eligibility 
by clinical team
 
Obtain informed consent 
 
Baseline Assessments
Pre-treatment blood samples, baseline clinical, laboratory and 
and HRQoL questionnaires
 
 
FERRIC CARBOXYMALTOSE
1000mg in
100 ml 0.9% sodium chloride (saline)
(Adjust to 20 mg/kg if weight <50 kg)
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Study visit
Infusion of IMP
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Monitoring of blood pressures and pulse before, 
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time
 
Follow-up assessments
Hospital discharge 
Day 28 from randomisation
Day 90 from randomisation
 
Randomisation
 
Page 18 of 30
https://mc.manuscriptcentral.com/inc
Journal of the Intensive Care Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 19 of 30
https://mc.manuscriptcentral.com/inc
Journal of the Intensive Care Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Figure 2. CONSORT pilot and feasibility trials flow diagram schematic
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Table 1. Timing of visits and data collection
Baseline (pre-
randomisation)
 Confirmation with inclusion and exclusion criteria
 Date and time of consent
 Patient demographics (age, sex, weight)
 Documented history of pre-existing anaemia prior to ICU admission
 Charlson Co-morbidity Index
 ICU admission – date and time of admission, ICU admission 
category, APACHE II score
 ICU organ support – duration and requirement (advanced 
respiratory, cardiovascular and renal support using the Critical Care 
Minimum Dataset definitions)
 Date and time of ICU discharge, ICU length of stay
 Blood product administration (red cells, platelets, fresh frozen 
plasma, cryoprecipitate) 
 Hb – ICU admission and ICU discharge
 Research blood samples (FBC, U&Es, LFTs, calcium, phosphate, 
iron profiles*, Vitamin D, EPO, hepcidin, sTfR
 Last recorded PaO2 and SaO2 with corresponding FiO2 time point 
closest to ICU discharge 
 Pregnancy test result (if indicated)
 HRQoL questionnaires (EQ-5D-5L, MFI-20, FACIT-F)
Hospital discharge  Nosocomial infection 
 Survival status
 ICU readmissions (if any)
 Total hospital length of stay
 Post-ICU blood product administration
 Adverse events
Day 28  Research blood samples (FBC, U&Es, LFTs, calcium, phosphate, 
iron profiles*, Vitamin D, EPO, hepcidin, sTfR
 HRQoL questionnaires (EQ-5D-5L, MFI-20, FACIT-F)
 Bespoke questionnaires for participants use of health and social 
care resources
 Adverse events
Page 22 of 30
https://mc.manuscriptcentral.com/inc
Journal of the Intensive Care Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Day 90  Research blood samples (FBC, U&Es, LFTs, calcium, phosphate, 
iron profiles*, Vitamin D, EPO, hepcidin, sTfR
 HRQoL questionnaires (EQ-5D-5L, MFI-20, FACIT-F)
 Bespoke questionnaires for participants use of health and social 
care resources
 Adverse events
*includes ferritin, serum iron, transferrin and transferrin saturation (%)
APACHEII, Acute Physiology and Chronic Health Evaluation II; EQ-5D-5L, EuroQol-5Dimension-5Level; 
EPO, erythropoietin; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FBC, Full Blood 
Count; Hb, Haemoglobin; LFTs; HRQoL, Health-related quality of life; ICU, Intensive Care Unit, Liver 
Function Tests; MFI-20, Multidimensional Fatigue Inventory-20; sTfR, soluble transferrin receptor; U&Es, 
Urea and Electrolytes 
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Table 2. ‘Traffic light’ system to determine progression to a definitive trial
Recruitment Protocol adherence Outcome Data
Green (Go) 8-11 participants per 
month across two 
centres
<5% failure to 
receive allocated 
intervention in the IV 
iron group
At least 80% of 
survivors will 
provide follow-up 
data at 90 days
Amber (Amend) 4-8 participants per 
month
5-10% failure to 
receive allocated 
intervention in the IV 
iron group
60-80% of survivors 
will provide follow-
up data at 90 days
Red (Stop) Less than 4 patients 
per month
>10% failure to 
receive allocated 
intervention in the IV 
iron group
50-60% of survivors 
will provide follow-
up data at 90 days
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*
Section/item ItemNo Description Page
Administrative information
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym 1
2a Trial identifier and registry name. If not yet registered, name of intended registry 1Trial registration
2b All items from the World Health Organization Trial Registration Data Set
Protocol version 3 Date and version identifier N/A
Funding 4 Sources and types of financial, material, and other support 13
5a Names, affiliations, and roles of protocol contributors 13Roles and 
responsibilities
5b Name and contact information for the trial sponsor 13
5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities
13
5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee)
10
Introduction
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Background and 
rationale
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention
3
6b Explanation for choice of comparators N/A
Objectives 7 Specific objectives or hypotheses 4
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
4, 5
Methods: Participants, interventions, and outcomes
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained
5
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, surgeons, psychotherapists)
5
11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 
administered
6
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or improving/worsening disease)
6
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 
(eg, drug tablet return, laboratory tests)
N/A
Interventions
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 6
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3
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation 
(eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended
6, 7
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits 
for participants. A schematic diagram is highly recommended (see Figure)
Figure 
1
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, 
including clinical and statistical assumptions supporting any sample size calculations
7
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 7
Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence 
generation
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol 
participants or assign interventions
7
Allocation 
concealment 
mechanism
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
N/A
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 
interventions
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 
assessors, data analysts), and how
N/A
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17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a 
participant’s allocated intervention during the trial
N/A
Methods: Data collection, management, and analysis
Data collection 
methods
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description 
of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol
7
18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols
8
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data 
quality (eg, double data entry; range checks for data values). Reference to where details of data 
management procedures can be found, if not in the protocol
8
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of 
the statistical analysis plan can be found, if not in the protocol
9
20b Methods for any additional analyses (eg, subgroup and adjusted analyses) N/A
20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple imputation)
9, 10
Methods: Monitoring
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement 
of whether it is independent from the sponsor and competing interests; and reference to where further 
details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is 
not needed
10
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21b Description of any interim analyses and stopping guidelines, including who will have access to these 
interim results and make the final decision to terminate the trial
10
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct
10
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor
10
Ethics and dissemination
Research ethics 
approval
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 11
Protocol amendments 25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators)
11
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32)
11
26b Additional consent provisions for collection and use of participant data and biological specimens in 
ancillary studies, if applicable
N/A
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and 
maintained in order to protect confidentiality before, during, and after the trial
11
Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each study site 13
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that 
limit such access for investigators
13
Ancillary and post-trial 
care
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from 
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6
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions
12
31b Authorship eligibility guidelines and any intended use of professional writers 12
31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code N/A
Appendices
Informed consent 
materials
32 Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on 
the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative 
Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.
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EXECUTIVE SUMMARY
Anaemia during intensive care unit (ICU) care is very common, affecting 60-80% of patients. Furthermore, 
around 80-90% of ICU survivors will be discharged from hospital with some degree of anaemia and will often 
receive no intervention or further investigation. Up to half of these patients will have persisting anaemia 
three to six months later. Persisting anaemia in ICU survivors has been demonstrated to be associated with 
poor health related quality of life, low physical function scores and high levels of fatigue. This is important 
because recent evidence suggests that a significant proportion of these patients have evidence of absolute 
and/or relative iron deficiency, which is largely untreated. 
Improving recovery from critical illness is a recognised research priority. In non-critically ill patients, treating 
anaemia with intravenous iron has resulted in meaningful improvements in quality of life, but uncertainties 
regarding the benefits, risks, timing and optimal route of iron therapy in survivors of critical illness remain. 
Prior to embarking on a phase III, multicentre trial, a carefully designed and implemented feasibility trial is 
essential. 
INtravenous Iron to Treat Anaemia following CriTical care (INTACT) is an open- label, feasibility, parallel 
group, randomised controlled trial (RCT). The overarching aim is to assess the feasibility of a future, 
multicentre RCT. Participants with moderate to severe anaemia (haemoglobin < 100 g.l-1), who have 
required at least 24 hours of ICU care, and are now deemed medically stable for discharge from ICU by the 
attending physician will considered for inclusion. Included participants will undergo 1:1 randomisation to 
either a one-off dose of intravenous iron (1000mg ferric carboxymaltose) or usual medical care using 
minimisation and stratified on anaemia severity and ICU length of stay. Participants will be followed up at 
28- and 90-days post-randomisation.   We anticipate enrolling 130 participants across three intensive care 
units over a 52-week recruitment period. 
The primary outcome measures, which will be used to determine feasibility, are recruitment and 
randomisation rates, protocol adherence and completeness of follow-up. Secondary outcome measures 
include collecting clinical, laboratory, fatigue scores (MFI-20, FACIT-F), health-related quality of life (EQ-5D-
5L) and safety data to inform the power calculations of a future definitive trial. A prespecified ‘traffic light’ 
system will be used as a guide for progression to a definitive trial. The trial is being funded as part of an NIHR 
Doctorial Research Fellowship, sponsored by the University of Oxford and has been prospectively registered 
(ISRCTN 13721808).
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